The federal government’s own compounding page says the agency has identified serious adverse events with CJC-1295, including increased heart rate and a systemic vasodilatory reaction. That is the record behind a product sold on promises of youth, sleep and fat loss, and the page closes with the words “available clinical data are limited.”
CJC-1295 has real pharmacology, a thin and aging human record, and a market that has run far past both. CJC-1295 raises growth hormone and IGF-I in the human studies that exist, FDA lists serious adverse events including increased heart rate and vasodilation against it, and no FDA-approved CJC-1295 medicine appears in the federal label database.
Everything below comes from the primary documents. We have cited each one so you can open it yourself.
CJC-1295 Peptide: What FDA Wrote Down in Its Own Table
FDA keeps a page titled “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.” Its content is marked current as of 22 April 2026. CJC-1295 appears on it, with this text under the heading “Potential significant safety risks”:
“Compounded drugs containing CJC-1295 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to for peptide-related impurities and API characterization. FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.”
Immunogenicity. Impurities. Serious adverse events. Clinical data limited. That is the agency’s own summary of the molecule, written for a compounding audience, and it is the closest thing to an official risk statement that exists for a peptide with no approved product.
One detail matters for anyone quoting this page. CJC-1295 sits in the second table, headed “Bulk drug substances nominated but withdrawn,” which the page describes as substances previously in category 2 of the interim policies whose nominations the nominators withdrew. FDA flagged the molecule. The risk language did not.
Teichman 2006: The Human Record Is Three Papers and a Decade Old
The human evidence for CJC-1295 comes from three published papers, all in healthy volunteers, all between 2006 and 2009.
The first is Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism, March 2006, volume 91, pages 799 to 805, online 13 December 2005. Two randomized, placebo-controlled, double-blind, ascending-dose trials, running 28 and 49 days, in healthy subjects aged 21 to 61. After a single subcutaneous injection, mean plasma growth hormone rose two to ten fold for six days or more, and mean IGF-I rose 1.5 to three fold for nine to eleven days. Estimated half-life was 5.8 to 8.1 days. After multiple doses, IGF-I stayed above baseline for up to 28 days. The authors reported that no serious adverse reactions occurred, and that the drug was relatively well tolerated, particularly at the trial doses of 30 or 60 micrograms per kilogram.
The second is Ionescu and Frohman, same journal, December 2006, volume 91, pages 4792 to 4797. They drew blood at 20 minute intervals across a 12 hour overnight window in healthy men aged 20 to 40, before and one week after a single injection of 60 or 90 micrograms per kilogram. Trough growth hormone rose 7.5 fold, mean growth hormone rose 46 percent, and IGF-I rose 45 percent. Pulse frequency and pulse size did not change. The drug raised the floor, not the peaks.
The third is Sackmann-Sala and colleagues in Growth Hormone and IGF Research, December 2009, pages 471 to 477, which ran serum from 11 healthy young men through two-dimensional gel electrophoresis and found protein shifts after treatment.
That is the entire human foundation under a product sold by the vial to people who have none of those characteristics.
The second study also explains why this peptide behaves differently from the growth hormone releasing hormone your body makes. CJC-1295 carries a drug affinity complex that binds to albumin in the blood, which is where the multi-day half-life comes from. A long half-life is a pharmacokinetic achievement. It is also the reason a single unverified dose keeps working on a body for a week.
NCT00267527: The One Registered Trial Was Terminated
We searched the federal trial registry three ways, for CJC-1295, CJC 1295 and CJC1295. One study came back.
NCT00267527, “A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity.” Phase 2. Start date December 2005. Planned enrollment 120. Status: terminated.
That is the registry’s record, and we are reporting exactly what it says. The record does not publish the reason for termination, and we will not invent one. Two things follow from it anyway. The only registered study of this molecule was aimed at visceral fat in people living with HIV, a serious medical population, not at appearance. And it did not finish.
Anyone selling CJC-1295 for skin, sleep or a leaner waist is selling into the space where a terminated trial used to be.
Increased Heart Rate: Two Documents That Do Not Agree
Here is the part that took us longest to write. The 2006 trial paper says no serious adverse reactions occurred. FDA’s current page names serious adverse events, including increased heart rate and a systemic vasodilatory reaction.
Those two statements do not reconcile, and the public record does not let us settle it. FDA does not publish the case reports behind that table row. The trial report describes selected volunteers under close monitoring, which is a different population from anyone buying a vial online. A vasodilatory reaction is consistent with what growth hormone releasing hormone activity does to blood vessels, which makes the agency’s wording plausible rather than surprising.
So we are not going to resolve the conflict. We are going to name it, because the sellers repeat the trial’s sentence and drop the agency’s. Both sentences exist.
The Forum Record: 23 Threads, Nine Sites, One Peer-Reviewed Study
The most rigorous published study of CJC-1295 users is not a trial. It is a netnography by Van Hout and Hearne in Substance Use and Misuse, January 2016, volume 51, pages 73 to 84.
They searched the web for variations of “CJC-1295” combined with “forum,” found 96 hits on bodybuilding sites, filtered to female use, and ended with nine sites and 23 discussion threads. Their findings: users chose the peptide for weight loss, muscle enhancement, youthful skin, improved sleep and injury healing. Users also worried, in their own threads, that female dosing is guesswork, because growth hormone pulses differ by sex and the published papers carried no female data to copy.
Those concerns were correct. There is no female dosing data in the three papers above. The women in those 23 threads were trading numbers in a vacuum, and the study that documented them says so in its own conclusion, which calls for public health attention to self-medicating use.
CJC-1295 Peptide Versus the Neighbor on the Shelf
CJC-1295 is rarely sold alone. It is sold beside ipamorelin, sermorelin, MOTS-c and a rotating cast of other peptides, each carrying a different federal paper trail. Sermorelin carries its own record, which we covered separately at Sermorelin Side Effects: The Label That Left the Shelf.
The difference worth understanding is regulatory, not chemical. A bulk substance used by a compounding pharmacy is not an approved drug, and a compounded preparation is not the product that appeared in a trial. FDA states that plainly across its compounding pages. If a clinic says “the same peptide used in clinical trials,” the honest question back is: same molecule, which trial, and which laboratory made this vial.
Our wider map of which peptides carry which risk language is at Peptides Side Effects: What FDA Has Published, and the general safety framework is at Are Peptides Safe? The Answer Depends on the Vial. The MOTS-c failure mode, where FDA found no human exposure data at all, is documented at MOTS-c Dosage: Zero Milligrams.
What to Ask Before Paying for a CJC-1295 Peptide
Four questions, in this order.
Which trial are you citing? If the answer is not Teichman 2006, Ionescu 2006 or Sackmann-Sala 2009, ask for the citation and read it before you pay.
Which population was in that trial? Healthy volunteers aged 21 to 61, mostly men, under monitored conditions. If you are not that, the data are being borrowed.
Who made this vial, and is the pharmacy licensed in my state? Compounding pharmacy rules are state level as well as federal, and a legitimate seller answers this without flinching.
Who is prescribing, and what happens at month three? A peptide sold with no prescriber and no follow-up is a transaction, not care.
We do not publish doses, and this article contains none. Doses vary by preparation, and the only person who should set one is the prescriber holding your history. When you are ready to compare providers, our clinic directory lists them by city.
Frequently asked questions
Is CJC-1295 peptide FDA approved?
No FDA-approved CJC-1295 medicine exists. FDA treats it as a bulk drug substance for compounding, and its page on substances that may present significant safety risks still carries the molecule’s risk language from when it sat in category 2 of the interim policies. The federal label database holds one listing for the molecule, a bulk ingredient entry from AX Pharmaceutical published 16 August 2016, which is a supplier record, not an approved drug.
What are the side effects of CJC-1295?
FDA’s published risk text names serious adverse events including increased heart rate and a systemic vasodilatory reaction, plus immunogenicity and peptide impurity concerns for certain routes of administration. The 2006 trial paper reported no serious adverse reactions in monitored healthy volunteers. Those two statements conflict, and FDA does not publish the underlying case data that would explain why. Injection site reactions, flushing and water retention are commonly described in user accounts, which are not evidence of frequency.
Does CJC-1295 raise growth hormone?
Yes, in the studies that exist. A single injection raised mean growth hormone two to ten fold for six days or more and IGF-I 1.5 to three fold for nine to eleven days in healthy adults, with an estimated half-life of 5.8 to 8.1 days. A separate study found trough growth hormone up 7.5 fold with pulse frequency unchanged. No study shows that this produces meaningful fat loss, muscle gain or skin change in people buying vials today.
Is it legal to buy CJC-1295 online?
A vial sold to you directly, with no prescription and no licensed pharmacy in the chain, is not a lawful prescription medicine, whatever the website says. Legitimate access runs through a licensed prescriber and a licensed compounding pharmacy. Our guide to checking a clinic’s credentials is at How to Check a Peptide Clinic Before Booking. We are not your lawyer, and state rules vary.
How long does CJC-1295 stay in your system?
The published estimate is a half-life of 5.8 to 8.1 days, from the 2006 trial. IGF-I stayed above baseline for up to 28 days after multiple doses. Those figures describe trial participants, not a prediction for any individual.
Does CJC-1295 build muscle?
No published trial measured muscle mass or strength with CJC-1295. The evidence covers growth hormone and IGF-I blood levels, not body composition outcomes. Users in the published netnography named muscle enhancement as a reason for use, which is a statement about belief, not a result.
Why did the only registered CJC-1295 trial stop?
The registry record for NCT00267527 lists the study as terminated and does not publish a reason. We will not guess. Anyone who tells you the reason with confidence should be able to show you a document.
Sources: FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, content current as of 22 April 2026. Teichman SL et al., Journal of Clinical Endocrinology and Metabolism, March 2006;91(3):799-805, published online 13 December 2005. Ionescu M and Frohman LA, Journal of Clinical Endocrinology and Metabolism, December 2006;91(12):4792-4797. Sackmann-Sala L et al., Growth Hormone and IGF Research, December 2009;19(6):471-477. Van Hout MC and Hearne E, Substance Use and Misuse, 2016;51(1):73-84. ClinicalTrials.gov, NCT00267527, A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity, accessed 24 October 2026. DailyMed, AX Pharmaceutical GRF 1-29 (CJC1295) bulk ingredient listing, NDC 62157-251, published 16 August 2016.
This article is general information for people comparing peptide clinics. It is not medical advice, it is not a recommendation for or against any product, and it contains no dosing guidance. Compounded preparations are not FDA-approved drugs, and the products sold online are not the products studied in the trials cited above. Talk to a licensed prescriber about your own history before starting, stopping or changing anything.